The use of nephron-sparing intervention does not appear to be compromised after a period of active surveillance for patients with cT1 renal masses.
Wang M, Wilke A, Goorman S, McElroy A, Vercnocke J, Moser AM, Van Til M, Semerjian A, Mirza M, Maatman T, Kozminski M, Rogers CG, Lane BR, Ginsburg K; Michigan Urological Surgery Improvement Collaborative.
Wang M, et al. Among authors: moser am.
Urol Oncol. 2024 Nov 15:S1078-1439(24)00710-5. doi: 10.1016/j.urolonc.2024.10.034. Online ahead of print.
Urol Oncol. 2024.
PMID: 39550302